Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > scleroderma therapeutics market
Get a free sample of Scleroderma Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Scleroderma Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market has seen significant industrial developments, including the introduction of novel biologics and targeted therapies. Companies are increasingly focusing on immunosuppressors and antifibrotic agents to manage the disease's complex symptoms. Recent advancements include the FDA approval of Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease, highlighting a trend towards more specialized treatments. Collaborative research initiatives and partnerships are accelerating the development of new drugs. Additionally, the market is witnessing increased investment in clinical trials aimed at expanding the indications for existing drugs. These developments are enhancing treatment options and improving patient outcomes, driving the market forward.
Prominent players operating in the scleroderma therapeutics industry include:
Scleroderma therapeutics industry from the immunosuppressors segment reached USD 781.6 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their pivotal role in managing systemic scleroderma.
North America scleroderma therapeutics industry is expected to register 5.3% CAGR from 2024-2032 due to increasing prevalence of the disease and heightened awareness among healthcare professionals and patients in the region.
Scleroderma therapeutics market size was USD 2.2 billion in 2023 and is expected to register 6.8% CAGR from 2024-2032 due to increasing prevalence of the condition and rising awareness amongst patients worldwide.
Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Galderma Laboratories, Genkyotex, Gilead Sciences, GSK plc, Pfizer, Inc., Prometic Life Sciences, Inc., F. Hoffmann La Roche Ltd., Sanofi SA, and United Therapeutics, are some of the major scleroderma therapeutics companies worldwide.